Filing Flows › Bicycle Therapeutics (BCYC) › Q2 2026 › vs Q1 2026
Bicycle Therapeutics (BCYC) Q2 2026 vs Q1 2026 (quarter over quarter)
Bicycle Therapeutics's revenue fell $258K (-29%) from $887K in Q1 2026 to $629K in Q2 2026.
Bicycle Therapeutics, Q2 2026: revenue $629K (-78% year over year), net loss $50.3M, operating cash flow −$49.6M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $629K | $887K | −$258K | -29% |
| Other income, net | $4.3M | $4.8M | −$513K | -11% |
| Net loss | $50.3M | $60.8M | −$10.5M | -17% |
| Costs & expenses | $55.3M | $66.5M | −$11.3M | -17% |
| Operating costs | $55.2M | $66.4M | −$11.2M | -17% |
| Income tax | $90K | $172K | −$82K | -48% |
| Research & development | $41.2M | $48.9M | −$7.7M | -16% |
| General & admin | $14.0M | $17.5M | −$3.4M | -20% |
| Operating cash sources | $57.1M | $74.0M | −$16.9M | -23% |
| Depreciation & amortization | $1.1M | $1.1M | −$62K | -5% |
| Share-based compensation | $6.4M | $6.9M | −$526K | -8% |
| Cash used in operations | $49.6M | $65.9M | −$16.3M | -25% |
| Net loss absorbed | $50.3M | $60.8M | −$10.5M | -17% |
| Working capital & other | $6.7M | $13.2M | −$6.4M | -49% |
Questions
How much did Bicycle Therapeutics's revenue grow quarter over quarter in Q2 2026?
Bicycle Therapeutics's revenue fell $258K (-29%) from $887K in Q1 2026 to $629K in Q2 2026.